Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years due to Washington's demand for sensitive biological samples.
This rejection became public following a official document from December was disclosed, indicating that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
A government spokesperson has since clarified that the US was requesting genetic material for scientific study and commercial purposes but was unwilling to share the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued dialogue to find a agreement acceptable to both sides so the country's vital HIV treatment initiative can be sustained.
Wider Context
This rejection comes after a comparable case in neighbouring Kenya, where a court blocked a similar deal with the US after concerns were raised about the security of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and responsibility.
According to reports, 16 African countries have to date agreed to similar agreements, constituting more than $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our nation would supply the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our people if a new pandemic arise."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting structures already set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This system is designed to ensure that when a country contributes its information, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," he added.
"We are open to further dialogue with our US partners on how subsequent collaboration could be designed in a way that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts said it understood the government's concerns, but recommended that talks must proceed considering much of the country's HIV programmes were funded by external financing.
"If technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," the group said.
The situation underscores the continuing tensions between receiving crucial international aid and protecting national sovereignty in an ever more data-driven world.